Bullous Pemphigoid Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major bullous pemphigoid markets reached a value of US$ 245.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,379.3 Million by 2034, exhibiting a growth rate (CAGR) of 16.99% during 2024-2034.
The bullous pemphigoid market has been comprehensively analyzed in IMARC's new report titled "Bullous Pemphigoid Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bullous pemphigoid refers to a chronic autoimmune disorder that majorly affects the skin and mucous membranes, causing the formation of fluid-filled blisters, or bullae. It usually occurs when the immune system mistakenly attacks a protein named collagen, which is present in the skin and mucous membranes. This ailment usually starts with an itchy, raised rash, but as the condition develops, large blisters can form on the skin. These blisters typically appear on the arms, legs, and torso but can also affect the mouth, eyes, and genital region. Individuals suffering from bullous pemphigoid may experience intense burning, stinging, painful sores, along with redness and swelling of the affected area. The diagnosis of this disease requires a detailed evaluation of the patient’s symptoms and medical history. Blood tests and immunofluorescence testing of skin and serum are also utilized to validate abnormalities within the body. The healthcare provider may perform a biopsy that involves the removal of a small skin region and its laboratory examination.
The increasing cases of immune-mediated diseases that can trigger inflammation due to overactivation of the antibodies within the body are primarily driving the bullous pemphigoid market. Furthermore, the rising prevalence of exposure to ultraviolet light and ionizing radiation, resulting in premature aging and damage to the skin, is also propelling the market growth. In addition to this, the escalating utilization of various steroid-sparing drugs, including azathioprine, dapsone, mycophenolate mofetil, etc., which can ease symptoms like pain and itching, is further creating a positive outlook for the market. Moreover, the inflating usage of enzyme-linked immunosorbent assay (ELISA) for diagnosis of the ailment and to determine response to treatment is also bolstering the market growth. Apart from this, the emerging popularity of low-level laser therapies, since they are less uncomfortable and offer faster wound healing as compared to other conventional medications, is acting as another significant growth-inducing factor. Additionally, the widespread adoption of a monoclonal antibody that targets mast cell degranulation, which reduces the formation of blisters, is expected to drive the bullous pemphigoid market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the bullous pemphigoid market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bullous pemphigoid and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bullous pemphigoid market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bullous pemphigoid market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bullous pemphigoid market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bullous pemphigoid marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bullous pemphigoid market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bullous pemphigoid market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bullous pemphigoid market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bullous pemphigoid across the seven major markets?
What is the number of prevalent cases (2018-2034) of bullous pemphigoid by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bullous pemphigoid by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bullous pemphigoid across the seven major markets?
What is the size of the bullous pemphigoid patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bullous pemphigoid?
What will be the growth rate of patients across the seven major markets?
Bullous Pemphigoid: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bullous pemphigoid drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bullous pemphigoid market?
What are the key regulatory events related to the bullous pemphigoid market?
What is the structure of clinical trial landscape by status related to the bullous pemphigoid market?
What is the structure of clinical trial landscape by phase related to the bullous pemphigoid market?
What is the structure of clinical trial landscape by route of administration related to the bullous pemphigoid market?
The bullous pemphigoid market has been comprehensively analyzed in IMARC's new report titled "Bullous Pemphigoid Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bullous pemphigoid refers to a chronic autoimmune disorder that majorly affects the skin and mucous membranes, causing the formation of fluid-filled blisters, or bullae. It usually occurs when the immune system mistakenly attacks a protein named collagen, which is present in the skin and mucous membranes. This ailment usually starts with an itchy, raised rash, but as the condition develops, large blisters can form on the skin. These blisters typically appear on the arms, legs, and torso but can also affect the mouth, eyes, and genital region. Individuals suffering from bullous pemphigoid may experience intense burning, stinging, painful sores, along with redness and swelling of the affected area. The diagnosis of this disease requires a detailed evaluation of the patient’s symptoms and medical history. Blood tests and immunofluorescence testing of skin and serum are also utilized to validate abnormalities within the body. The healthcare provider may perform a biopsy that involves the removal of a small skin region and its laboratory examination.
The increasing cases of immune-mediated diseases that can trigger inflammation due to overactivation of the antibodies within the body are primarily driving the bullous pemphigoid market. Furthermore, the rising prevalence of exposure to ultraviolet light and ionizing radiation, resulting in premature aging and damage to the skin, is also propelling the market growth. In addition to this, the escalating utilization of various steroid-sparing drugs, including azathioprine, dapsone, mycophenolate mofetil, etc., which can ease symptoms like pain and itching, is further creating a positive outlook for the market. Moreover, the inflating usage of enzyme-linked immunosorbent assay (ELISA) for diagnosis of the ailment and to determine response to treatment is also bolstering the market growth. Apart from this, the emerging popularity of low-level laser therapies, since they are less uncomfortable and offer faster wound healing as compared to other conventional medications, is acting as another significant growth-inducing factor. Additionally, the widespread adoption of a monoclonal antibody that targets mast cell degranulation, which reduces the formation of blisters, is expected to drive the bullous pemphigoid market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the bullous pemphigoid market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for bullous pemphigoid and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bullous pemphigoid market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the bullous pemphigoid market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the bullous pemphigoid market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current bullous pemphigoid marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the bullous pemphigoid market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the bullous pemphigoid market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the bullous pemphigoid market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of bullous pemphigoid across the seven major markets?
What is the number of prevalent cases (2018-2034) of bullous pemphigoid by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of bullous pemphigoid by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with bullous pemphigoid across the seven major markets?
What is the size of the bullous pemphigoid patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of bullous pemphigoid?
What will be the growth rate of patients across the seven major markets?
Bullous Pemphigoid: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for bullous pemphigoid drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bullous pemphigoid market?
What are the key regulatory events related to the bullous pemphigoid market?
What is the structure of clinical trial landscape by status related to the bullous pemphigoid market?
What is the structure of clinical trial landscape by phase related to the bullous pemphigoid market?
What is the structure of clinical trial landscape by route of administration related to the bullous pemphigoid market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BULLOUS PEMPHIGOID - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BULLOUS PEMPHIGOID - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BULLOUS PEMPHIGOID - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BULLOUS PEMPHIGOID - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BULLOUS PEMPHIGOID - UNMET NEEDS
10 BULLOUS PEMPHIGOID - KEY ENDPOINTS OF TREATMENT
11 BULLOUS PEMPHIGOID - MARKETED PRODUCTS
11.1 List of Bullous Pemphigoid Marketed Drugs Across the Top 7 Markets
11.1.1 Kenketu Glovenin I (Immune globulin) - Nihon Pharmaceutical
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BULLOUS PEMPHIGOID - PIPELINE DRUGS
12.1 List of Bullous Pemphigoid Pipeline Drugs Across the Top 7 Markets
12.1.1 Dupilumab - Regeneron/Sanofi
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Efgartigimod PH20 SC - argenx
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AKST 4290 - Alkahest
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Ixekizumab - Eli Lilly and Company
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Benralizumab - AstraZeneca/Kyowa Kirin
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BULLOUS PEMPHIGOID - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BULLOUS PEMPHIGOID – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BULLOUS PEMPHIGOID - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bullous Pemphigoid - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bullous Pemphigoid - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bullous Pemphigoid - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bullous Pemphigoid - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bullous Pemphigoid - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bullous Pemphigoid - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bullous Pemphigoid - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bullous Pemphigoid - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bullous Pemphigoid - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bullous Pemphigoid - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bullous Pemphigoid - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bullous Pemphigoid - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bullous Pemphigoid - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bullous Pemphigoid - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bullous Pemphigoid - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bullous Pemphigoid - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bullous Pemphigoid - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bullous Pemphigoid - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bullous Pemphigoid - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bullous Pemphigoid - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bullous Pemphigoid - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bullous Pemphigoid - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bullous Pemphigoid - Access and Reimbursement Overview
16 BULLOUS PEMPHIGOID - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BULLOUS PEMPHIGOID MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BULLOUS PEMPHIGOID MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BULLOUS PEMPHIGOID - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BULLOUS PEMPHIGOID - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BULLOUS PEMPHIGOID - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 BULLOUS PEMPHIGOID - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BULLOUS PEMPHIGOID - UNMET NEEDS
10 BULLOUS PEMPHIGOID - KEY ENDPOINTS OF TREATMENT
11 BULLOUS PEMPHIGOID - MARKETED PRODUCTS
11.1 List of Bullous Pemphigoid Marketed Drugs Across the Top 7 Markets
11.1.1 Kenketu Glovenin I (Immune globulin) - Nihon Pharmaceutical
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BULLOUS PEMPHIGOID - PIPELINE DRUGS
12.1 List of Bullous Pemphigoid Pipeline Drugs Across the Top 7 Markets
12.1.1 Dupilumab - Regeneron/Sanofi
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Efgartigimod PH20 SC - argenx
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AKST 4290 - Alkahest
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Ixekizumab - Eli Lilly and Company
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Benralizumab - AstraZeneca/Kyowa Kirin
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. BULLOUS PEMPHIGOID - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BULLOUS PEMPHIGOID – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BULLOUS PEMPHIGOID - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Bullous Pemphigoid - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Bullous Pemphigoid - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Bullous Pemphigoid - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Bullous Pemphigoid - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Bullous Pemphigoid - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Bullous Pemphigoid - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Bullous Pemphigoid - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Bullous Pemphigoid - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Bullous Pemphigoid - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Bullous Pemphigoid - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Bullous Pemphigoid - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Bullous Pemphigoid - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Bullous Pemphigoid - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Bullous Pemphigoid - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Bullous Pemphigoid - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Bullous Pemphigoid - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Bullous Pemphigoid - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Bullous Pemphigoid - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Bullous Pemphigoid - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Bullous Pemphigoid - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Bullous Pemphigoid - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Bullous Pemphigoid - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Bullous Pemphigoid - Access and Reimbursement Overview
16 BULLOUS PEMPHIGOID - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BULLOUS PEMPHIGOID MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BULLOUS PEMPHIGOID MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
